This information is intended for UK healthcare professionals only. Prescribing Information can be found at the bottom of the page. This information is intended to be viewed on a standard desktop computer.

teva

Adverse events should be reported: Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Teva online, or tel: 0207 540 7117 or email: medinfo@tevauk.com.

 

About DuoResp® Spiromax® (budesonide/formoterol)

DuoResp® Spiromax® is indicated in:1
Asthma: Adults and adolescents aged 12 and over for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate (i.e. in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists, or in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists)
COPD: Adults aged 18 and over for the symptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEV1) < 70% predicted normal (post bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.

Max and maxine.png

DuoRespSpiromax-inhalers-duo.png

DuoResp® Spiromax® is available in two strengths:1

• 160 mcg/4.5 mcg (delivered dose) which has a metered dose of 200 mcg/6 mcg

• 320 mcg/9 mcg (delivered dose) which has a metered dose of 400 mcg/12 mcg

DuoResp® Spiromax® 160 mcg/4.5 mcg is a Maintenance and Reliever Therapy (MART) licensed inhaler in appropriate patients with asthma aged 12 years and older.1 When on a MART regimen, patients may take their inhaler as needed in addition to their maintenance dose. No more than six inhalations should be taken on any single occasion. Patients using more than eight inhalations daily should be strongly advised to seek medical advice. They should be reassessed and their maintenance therapy should be reconsidered. Additionally, no more than 12 inhalations should be taken in total within 24 hours.1

CO2 Measured Footprint Logo.png The carbon footprint of DuoResp® Spiromax® has been measured and certified as 0.63 kgCO2e by The Carbon Trust.*2

 

COPD: Chronic obstructive pulmonary disease
*The figure supplied is based on 93 actuations per device – this average was calculated from the number of 160 mcg/4.5 mcg 120 dose inhalers and the number of 320 mcg/9 mcg 60 dose inhalers manufactured during the data recording period sampled in 2020.

References:

1. DuoResp® Spiromax® Summary of Product Characteristics.
2. Teva UK Limited. Data on File 226.

DuoResp® Spiromax® (budesonide / formoterol) Prescribing Information Request a placebo device

t

Adverse events should be reported: Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Teva online, or tel: 0207 540 7117 or email: medinfo@tevauk.com.
Date of preparation: September 2022
Reference: DUOR-GB-00156

Copyright © 2022 Teva UK Limited.
Registered in England No. 302461. Registered office: Teva UK Limited, Whistler Drive, Castleford, WF10 5HX 
+44 (0) 1977 628500 | www.tevauk.com | Contact Us

Teva Logo--100X35.png
Privacy Policy | Pharmacovigilance Privacy PolicyTerms and Conditions  | AccessibilityReporting Adverse Events